Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.35 +5.0%	$2.97	$2.07 ▼ $4.20	$104.04M	0.39	104,338 shs	38,261 shs
AVTX Avalo Therapeutics	$5.01 +1.4%	$4.44	$3.39 ▼ $16.00	$53.71M	0.77	63,829 shs	22,006 shs
CTXR Citius Pharmaceuticals	$2.20 +4.5%	$0.98	$0.65 ▼ $26.25	$23.50M	1.23	756,713 shs	2.80 million shs
KPTI Karyopharm Therapeutics	$4.62 +0.2%	$4.97	$3.51 ▼ $16.95	$37.93M	0.24	76,635 shs	36,017 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	+4.04%	+20.07%	+32.41%	+48.23%
AVTX Avalo Therapeutics	0.00%	+4.81%	+15.17%	-13.62%	-56.96%
CTXR Citius Pharmaceuticals	0.00%	+43.46%	+151.14%	+116.26%	-81.91%
KPTI Karyopharm Therapeutics	0.00%	+5.24%	+6.45%	+19.69%	-62.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.6732 of 5 stars	3.6	3.0	0.0	1.1	3.3	0.0
AVTX Avalo Therapeutics	3.0634 of 5 stars	3.5	3.0	0.0	2.0	1.7	1.3
CTXR Citius Pharmaceuticals	2.1657 of 5 stars	3.4	2.0	0.0	1.1	0.8	1.3
KPTI Karyopharm Therapeutics	3.8541 of 5 stars	3.5	1.0	4.6	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	168.66% Upside
AVTX Avalo Therapeutics	3.00	Buy	$30.00	498.80% Upside
CTXR Citius Pharmaceuticals	2.80	Moderate Buy	$53.00	2,314.58% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	835.06% Upside

Current Analyst Ratings Breakdown

Latest CTXR, KPTI, AVTX, and ANIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	513.83	N/A	N/A	$0.46 per share	7.28
AVTX Avalo Therapeutics	$440K	123.31	N/A	N/A	$12.80 per share	0.39
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$10.25 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.27	N/A	N/A	($22.10) per share	-0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	111.00%	58.88%	8/11/2025 (Estimated)
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.76	N/A	N/A	-58.63%	-37.67%	8/11/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)

Latest CTXR, KPTI, AVTX, and ANIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/14/2025	Q2 2025	CTXR Citius Pharmaceuticals	-$1.08	-$1.27	-$0.19	-$1.27	N/A	N/A
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
AVTX Avalo Therapeutics	N/A	22.61	22.61
CTXR Citius Pharmaceuticals	N/A	0.37	0.06
KPTI Karyopharm Therapeutics	N/A	1.33	1.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
AVTX Avalo Therapeutics	87.06%
CTXR Citius Pharmaceuticals	16.88%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
AVTX Avalo Therapeutics	3.03%
CTXR Citius Pharmaceuticals	10.70%
KPTI Karyopharm Therapeutics	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.50 million	Not Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable

CTXR, KPTI, AVTX, and ANIX Headlines

Recent News About These Companies

Karyopharm Therapeutics Inc News (KPTI) - Investing.com

July 2 at 9:56 AM | investing.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Buy" from Brokerages

July 2 at 3:49 AM | americanbankingnews.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | prnewswire.com

Karyopharm to Present at the Jefferies Global Healthcare Conference

June 3, 2025 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | prnewswire.com

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

May 26, 2025 | zacks.com

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

May 19, 2025 | zacks.com

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025 | prnewswire.com

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025 | prnewswire.com

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025 | prnewswire.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 5.15%

May 6, 2025 | aaii.comA

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | prnewswire.com

Karyopharm Therapeutics Inc.DL-Exch. Notes 2018(25) Bond

May 1, 2025 | markets.businessinsider.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 5.06%

April 30, 2025 | aaii.comA

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Inc. Common Stock (KPTI)

April 23, 2025 | nasdaq.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | prnewswire.com

Karyopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler

March 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, KPTI, AVTX, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.35 +0.16 (+5.02%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$3.28 -0.08 (-2.24%)

As of 07/3/2025 04:43 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Avalo Therapeutics NASDAQ:AVTX

$5.01 +0.07 (+1.42%)

Closing price 07/3/2025 01:33 PM Eastern

Extended Trading

$5.01 0.00 (0.00%)

As of 07/3/2025 04:46 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Citius Pharmaceuticals NASDAQ:CTXR

$2.19 +0.10 (+4.52%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$2.22 +0.03 (+1.14%)

As of 07/3/2025 04:58 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Karyopharm Therapeutics NASDAQ:KPTI

$4.62 +0.01 (+0.22%)

Closing price 07/3/2025 02:45 PM Eastern

Extended Trading

$4.49 -0.13 (-2.81%)

As of 07/3/2025 04:28 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time